Cargando…

Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct‐acting antivirals—A prospective study

BACKGROUND AND AIM: No information exists regarding direct‐acting antivirals (DAAs) salvage therapy for Hepatitis C (HCV)‐infected patients with any type of cancer. We prospectively evaluated the safety and efficacy (SVR12) of salvage therapy in these patients. METHODS: Patients who failed initial D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pritchard, Haley, Jandhyala, Deeksha, Hosry, Jeff, Angelidakis, Georgios, Torres, Harrys A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273696/ https://www.ncbi.nlm.nih.gov/pubmed/32514467 http://dx.doi.org/10.1002/jgh3.12294

Ejemplares similares

Salvage Therapy in Cancer Patients With Hepatitis C Infection Failing Direct-Acting Antivirals: A Prospective Study
por: Pritchard, Haley, et al.
Publicado: (2017)

2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
por: Hosry, Jeff, et al.
Publicado: (2018)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Direct-acting Antivirals Induce Lymphoproliferative Disease Response in HCV-infected Patients: A Prospective Case Series
por: Hosry, Jeff, et al.
Publicado: (2017)

2197. Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals
por: Pritchard, Haley, et al.
Publicado: (2018)

2228. Late Viral Relapse After Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients
por: Angelidakis, Georgios, et al.
Publicado: (2018)

2226. Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series
por: Hosry, Jeff, et al.
Publicado: (2018)

Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals
por: Barbieri, Diego, et al.
Publicado: (2018)

Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals
por: Noureddin, Mazen, et al.
Publicado: (2018)

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
por: Cartwright, Emily J., et al.
Publicado: (2023)

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C
por: Pan, Jason J., et al.
Publicado: (2018)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
por: Hill, Andrew, et al.
Publicado: (2017)

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
por: Pham, Timothy T., et al.
Publicado: (2018)

Sustained Virologic Response with Direct Acting Antivirals in HIV Coinfected Hepatitis C Patients and Its Effect on Liver Fibrosis
por: Lebron, Dora, et al.
Publicado: (2017)

2222. Impact of Sustained Virologic Response Achieved Through Newer Direct Acting Antivirals in Hepatitis C Infection on Diabetes Mellitus
por: Mada, Pradeep Kumar, et al.
Publicado: (2018)

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma
por: Sohn, Won
Publicado: (2021)

Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Yoh, Kazunori, et al.
Publicado: (2017)

Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2020)

Risk factors for liver‐related mortality of patients with hepatitis C virus after sustained virologic response to direct‐acting antiviral agents
por: Hattori, Nobuhiro, et al.
Publicado: (2022)

Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals
por: Sparvoli, Jucéli Márcia Hendges, et al.
Publicado: (2023)

Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment
por: Hahn, Katherine J., et al.
Publicado: (2015)

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes
por: Piedade, Juliana, et al.
Publicado: (2021)

Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study
por: Colussi, GianLuca, et al.
Publicado: (2019)

Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents
por: Mashaal, Ahmed R, et al.
Publicado: (2022)

Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response
por: Pal, Vabhave, et al.
Publicado: (2020)

Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
por: Imamura, Taisuke, et al.
Publicado: (2022)

Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c
por: Dong, Tien S, et al.
Publicado: (2018)

Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study
por: Chang, Ming-Ling, et al.
Publicado: (2022)

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C
por: Yoshida, Yuji, et al.
Publicado: (2023)

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
por: D’Ambrosio, Roberta, et al.
Publicado: (2021)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
por: Tada, Toshifumi, et al.
Publicado: (2021)

Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response
por: Heo, Jeong
Publicado: (2011)

Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
por: Lodi, Sara, et al.
Publicado: (2022)

Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents
por: Huang, Chao-Min, et al.
Publicado: (2017)

Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct‐acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance
por: Tada, Toshifumi, et al.
Publicado: (2022)

Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer
por: Dandachi, Dima, et al.
Publicado: (2018)

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis
por: Kuwano, Toru, et al.
Publicado: (2018)

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
por: Struble, Kimberly, et al.
Publicado: (2019)

294. Hepatitis C Virologic Response in Hepatitis B and C Coinfected Persons Treated with Directly Acting Antiviral Agents: Results from ERCHIVES
por: Butt, Adeel A, et al.
Publicado: (2019)

Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
por: Minosse, Claudia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_huq33h97m3lkrtbpi5sd1ah13b